276 related articles for article (PubMed ID: 33676186)
1. Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells.
Ao J; Chiba T; Shibata S; Kurosugi A; Qiang N; Ma Y; Kan M; Iwanaga T; Sakuma T; Kanzaki H; Kanayama K; Kojima R; Kusakabe Y; Nakamura M; Saito T; Nakagawa R; Kondo T; Ogasawara S; Suzuki E; Muroyama R; Kato J; Mimura N; Kanda T; Maruyama H; Kato N
Biochem Biophys Res Commun; 2021 Apr; 549():171-178. PubMed ID: 33676186
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells.
Shi T; Iwama H; Fujita K; Kobara H; Nishiyama N; Fujihara S; Goda Y; Yoneyama H; Morishita A; Tani J; Yamada M; Nakahara M; Takuma K; Masaki T
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884875
[TBL] [Abstract][Full Text] [Related]
3. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
Fu R; Jiang S; Li J; Chen H; Zhang X
Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
[TBL] [Abstract][Full Text] [Related]
4. Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib.
Zhao Z; Song J; Zhang D; Wu F; Tu J; Ji J
Life Sci; 2021 Jan; 264():118642. PubMed ID: 33148422
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells.
Hamaya S; Fujihara S; Iwama H; Fujita K; Shi T; Nakabayashi R; Mizuo T; Takuma K; Nakahara M; Oura K; Tadokoro T; Mimura S; Tani J; Morishita A; Kobara H; Ono M; Himoto T; Masaki T
Anticancer Res; 2022 Mar; 42(3):1263-1275. PubMed ID: 35220216
[TBL] [Abstract][Full Text] [Related]
6. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
[TBL] [Abstract][Full Text] [Related]
7. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.
Matsuki M; Hoshi T; Yamamoto Y; Ikemori-Kawada M; Minoshima Y; Funahashi Y; Matsui J
Cancer Med; 2018 Jun; 7(6):2641-2653. PubMed ID: 29733511
[TBL] [Abstract][Full Text] [Related]
8. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression.
Zhao Z; Zhang D; Wu F; Tu J; Song J; Xu M; Ji J
J Cell Mol Med; 2021 Jan; 25(1):549-560. PubMed ID: 33210432
[TBL] [Abstract][Full Text] [Related]
9. EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells.
He X; Hikiba Y; Suzuki Y; Nakamori Y; Kanemaru Y; Sugimori M; Sato T; Nozaki A; Chuma M; Maeda S
Sci Rep; 2022 May; 12(1):8007. PubMed ID: 35568782
[TBL] [Abstract][Full Text] [Related]
10. Antitumor and Antiangiogenic Activities of Lenvatinib in Mouse Xenograft Models of Vascular Endothelial Growth Factor-Induced Hypervascular Human Hepatocellular Carcinoma.
Adachi Y; Matsuki M; Watanabe H; Takase K; Kodama K; Matsui J; Funahashi Y; Nomoto K
Cancer Invest; 2019; 37(4-5):185-198. PubMed ID: 31006280
[TBL] [Abstract][Full Text] [Related]
11. Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll-Like Receptor-Signaling Pathways in Human Hepatoma Cell Lines.
Sasaki R; Kanda T; Fujisawa M; Matsumoto N; Masuzaki R; Ogawa M; Matsuoka S; Kuroda K; Moriyama M
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397371
[TBL] [Abstract][Full Text] [Related]
12. Targeting LEF1-mediated epithelial-mesenchymal transition reverses lenvatinib resistance in hepatocellular carcinoma.
Li X; Su H; Tang W; Shu S; Zhao L; Sun J; Fan H
Invest New Drugs; 2024 Apr; 42(2):185-195. PubMed ID: 38372948
[TBL] [Abstract][Full Text] [Related]
13. Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma.
Huang S; Ma Z; Zhou Q; Wang A; Gong Y; Li Z; Wang S; Yan Q; Wang D; Hou B; Zhang C
Int J Biol Sci; 2022; 18(11):4357-4371. PubMed ID: 35864956
[No Abstract] [Full Text] [Related]
14. Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families.
He XX; Shi LL; Qiu MJ; Li QT; Wang MM; Xiong ZF; Yang SL
Biochem Biophys Res Commun; 2018 Oct; 504(4):878-884. PubMed ID: 30219235
[TBL] [Abstract][Full Text] [Related]
15. Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-κB axis associates with lenvatinib-inhibited progression in hepatocellular carcinoma in vitro and in vivo.
Wu CH; Hsu FT; Chao TL; Lee YH; Kuo YC
Biomed Pharmacother; 2022 Jan; 145():112437. PubMed ID: 34864311
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines
Ogasawara S; Mihara Y; Kondo R; Kusano H; Akiba J; Yano H
Anticancer Res; 2019 Nov; 39(11):5973-5982. PubMed ID: 31704822
[TBL] [Abstract][Full Text] [Related]
17. STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib.
Zheng Y; Huang C; Lu L; Yu K; Zhao J; Chen M; Liu L; Sun Q; Lin Z; Zheng J; Chen J; Zhang J
J Hematol Oncol; 2021 Jan; 14(1):16. PubMed ID: 33446239
[TBL] [Abstract][Full Text] [Related]
18. Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor.
Nakagawa T; Matsushima T; Kawano S; Nakazawa Y; Kato Y; Adachi Y; Abe T; Semba T; Yokoi A; Matsui J; Tsuruoka A; Funahashi Y
Cancer Sci; 2014 Jun; 105(6):723-30. PubMed ID: 24689876
[TBL] [Abstract][Full Text] [Related]
19. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.
Xu J; Zhang X; Wang H; Ge S; Gao T; Song L; Wang X; Li H; Qin Y; Zhang Z
Biomed Pharmacother; 2017 Apr; 88():421-429. PubMed ID: 28122307
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
